# Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin

Source: https://onco.cc/trials/nct04960709/  
OnCo record `nct04960709` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Durvalumab, Tremelimumab and Enfortumab vedotin in bladder & urothelial cancer, run by AstraZeneca, active and no longer recruiting.

## Summary

Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin is a phase 3 interventional study registered as NCT04960709 by AstraZeneca, with 712 participants enrolled, started 2021-08-05 and due to reach its primary completion in 2026-03-02. Interventions recorded: Durvalumab, Tremelimumab, Enfortumab Vedotin and Radical Cystectomy.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04960709
- Phase: 3
- Setting: A Phase III Randomized, Open-Label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab in Combination With Tremelimumab and Enfortumab Vedotin or Durvalumab in Combination With Enfortumab Vedotin for Perioperative Treatment in Patients Ineligible for Cisplatin or Who Refuse Cisplatin Undergoing Radical Cystectomy for Muscle Invasive Bladder Cancer (VOLGA)
- Sponsor: AstraZeneca
- Enrolled: 712

## Sources

- ClinicalTrials.gov NCT04960709: https://clinicaltrials.gov/study/NCT04960709

## Connected records

- cancers: [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/)
- drugs: [Durvalumab](https://onco.cc/drugs/durvalumab/), [Enfortumab vedotin](https://onco.cc/drugs/enfortumab-vedotin/), [Tremelimumab](https://onco.cc/drugs/tremelimumab/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)

---
JSON: https://onco.cc/api/v1/entities/nct04960709.json